Medical Retina Fellowship

医学视网膜奖学金

• 批准号: 10706221
• 负责人: Catherine Cukras
• 金额: $ 99.77万
• 依托单位: NATIONAL EYE INSTITUTE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10706221
• 关键词: Age related macular degeneration; Blood; Clinical; Clinical Research; Collaborations; Collection; DNA; Dark Adaptation; Diabetic Retinopathy; Epidemiology; Eye diseases; Faculty; Fellowship; Genotype; HIV; Hydroxychloroquine; Individual; Inherited; Intervention Studies; Medical; National Cancer Institute; National Eye Institute; National Human Genome Research Institute; National Institute of Neurological Disorders and Stroke; Natural History; Nerve Degeneration; Nursing Faculty; Participant; Patient Care; Patients; Phase; Phenotype; Protocols documentation; Resources; Retina; Retinal Diseases; Retinal Vein Occlusion; Serous; Telangiectasis; Testing; Toxic effect; Training; Translational Research; Von Hippel-Lindau Syndrome; X-Linked Retinoschisis; age related; biobank; clinical application; clinical care; clinical trial participant; epidemiology study; experience; follow-up; gene therapy; geographic atrophy; high standard; inhibitor; macula; novel; recruit; screening

A number of medical retinal protocols have been conducted at the National Eye Institute under the Division of Epidemiology and Clinical Applications. This includes both interventional studies (phase I and/or or II) and natural history studies for multiple common and rare retinal diseases. These include age-related macular degeneration (AMD), diabetic retinopathy, retinal vein occlusion, macular telangiectasia, hydroxychloroquine retinal toxicity, central serous chorioretinopathy, inherited retinal diseases, and Von Hippel Lindau (VHL) disease. In addition, a screening study provides participants for potential recruitment to these trials and natural history studies. The interventional studies include those related to treatment with a microglial inhibitor for geographic atrophy in AMD; novel treatments for retinal disease in VHL (in collaboration with the National Cancer Institute); a gene therapy approach for X-linked retinoschisis; and a neuroprotective treatment for macular telangiectasia type 2. The natural history studies include multiple related to AMD (follow up of Age-Related Eye Disease Study (AREDS) and AREDS2; studies of dark adaptation in patients with AMD; the AMD Ryan Initiative Study; the geographic atrophy natural history study), as well as those related to hydroxychloroquine retinal toxicity and macular telangiectasia. The Biobank protocol includes collection of blood (DNA) for multiple retinal diseases. Other collaborative studies underway include retinal findings in individuals with HIV-related neurodegeneration (with NINDS), and genotype-phenotype studies of AMD (with NHGRI).

流行病学和临床应用司下属的国家眼科研究所开展了若干视网膜医学规程。这包括介入研究（I期和/或II期）和多种常见和罕见视网膜疾病的自然史研究。这些疾病包括年龄相关性黄斑变性（AMD）、糖尿病视网膜病变、视网膜静脉阻塞、黄斑毛细血管扩张、羟氯喹视网膜毒性、中央浆液性脉络膜视网膜病变、遗传性视网膜疾病和Von Hippel Lindau （VHL）病。此外，筛选研究为这些试验和自然史研究的潜在招募提供了参与者。